Clinical trials: HIV Infection, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition HIV Infection
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
ANCA-IgG-positive ANCA Associated Vasculitis
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA…
- Trial name
- IDEAL (NCT06590545)
- Testing
- KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
- Volunteers
- 8 people
- Sponsor
- David Simon
Sepsis, Tuberculosis
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis
Sepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa…
- Trial name
- STARS (NCT07332325)
- Testing
- Hydrocortisone administration, Expanded antimicrobial therapy
- Where
- 4 sites in Tanzania, Uganda
- Volunteers
- 344 people
- Sponsor
- University of Virginia
Pneumocystis Jiroveci Pneumonia
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%.
- Trial name
- CAPSTONE-PJP (NCT07152613)
- Testing
- Saline (0.9%, sterile, for infusion), Low Dose Corticosteroids, Moderate dose corticosteroids
- Volunteers
- 240 people
- Sponsor
- Qingyuan Zhan
HIV
Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV
There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma.
- Trial name
- AbVax (NCT07054931)
- Testing
- ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv4
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University of Oxford
HIV, PrEP
Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services
The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC…
- Conditions
- HIV, PrEP, PrEP Adherence
- Trial name
- LYPS (NCT07438041)
- Testing
- LYPS, Enhanced Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Westat
HIV, HIV Infection
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day.
- Trial name
- Codivir® (NCT06676410)
- Testing
- ICF, Eligibility Assessment, Demographic data
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Code Pharma
Human Immunodeficiency Virus
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.
- Trial name
- NCT06424964
- Where
- Belgium
- Volunteers
- 600 people
- Sponsor
- Belgian Research on AIDS and HIV Consortium
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated…
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
- Trial name
- STARLIGHT-1 (NCT06343311)
- Testing
- EB103
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Estrella Immunopharma, Inc.
AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed…
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT07649304
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals
Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in HIV infected individuals, compared to non-HIV-infected individuals.
- Trial name
- YF-HIV (NCT03132311)
- Testing
- Yellow Fever vaccination (17 DD Biomanguinhos)
- Where
- Brazil
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV
Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community
The federal research award entitles "Long-acting injectable antiretroviral treatment to improve HIV treatment among justice-involved persons being released to the community" aims to Conduct interviews with justice and treatment…
- Trial name
- NCT06704204
- Testing
- The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks
- Volunteers
- 20 people
- Sponsor
- The Miriam Hospital
Monkeypox, Mpox
New York City Observational Study of Mpox Immunity
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose…
- Conditions
- Monkeypox, Mpox, HIV
- Trial name
- NYC OSMI (NCT05654883)
- Where
- United States
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
HIV Infected Individuals, HIV
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
Autologous CAR-T cell therapy in HIV-1/AIDS patients
- Trial name
- HIV-CAR-T (NCT06880380)
- Testing
- HIV-CAR-T
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV)
Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)
Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a…
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Trial name
- NCT06799702
- Testing
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Georgia
HIV-1
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT06252402
- Testing
- CMV/HIV-CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
AIDS
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
- Trial name
- NCT05939167
- Testing
- mesenchymal stem cell, saline
- Where
- 4 sites in China
- Volunteers
- 150 people
- Sponsor
- Cell Energy Life Sciences Group Co. LTD
HIV Prevention
WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women
HIV prevalence among transgender women (TW) in the United States is high (~14%). The best way to reduce HIV incidence in this population is to link TW to HIV pre-exposure prophylaxis (PrEP), which can reduce HIV transmission by…
- Trial name
- NCT06656676
- Testing
- WePrEP: A shared decision-making tool, Active comparator: CDC recommendations for discussing PrEP
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Colorado, Denver
Hepatitis E Virus Infection
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses…
- Trial name
- NCT06306196
- Testing
- Hecolin® Recombinant Hepatitis E Vaccine, Isotonic Sodium Chloride injection
- Where
- 3 sites in South Africa
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Stigma, HIV
Ending the HIV Epidemic: An All-facility Intervention for Patient and Healthcare Staff Well-being
The scope of this study is to engage Ryan White HIV/AIDS Program (RWHAP) funded organizations in the South/East US to co-develop context-responsive programs utilizing evidence-informed interventions to reduce stigma against…
- Conditions
- Stigma, HIV, Well-Being, Psychological
- Trial name
- NCT05785169
- Testing
- All-facility Training
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Columbia University